Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males
This study has been completed.
Sponsor:
Dynavax Technologies Corporation
Information provided by:
Dynavax Technologies Corporation
ClinicalTrials.gov Identifier:
NCT00599001
First received: January 11, 2008
Last updated: April 21, 2008
Last verified: April 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main purpose of this study is to assess the safety, tolerability, and biological activity of SD-101 compared with placebo in healthy male volunteers.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: SD-101 Drug: placebo |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Male Volunteers |
Further study details as provided by Dynavax Technologies Corporation:
Primary Outcome Measures:
- Proportion of subjects with and the amplitude and timing of adverse events, proportion of subjects with and the grade and timing of abnormal lab values, and proportion of subjects with and timing of changes in physical exam findings and vital signs [ Time Frame: Up to 7 days after dosing ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Pharmacokinetic parameters [ Time Frame: Up to 24 hours after dosing ] [ Designated as safety issue: No ]
- Levels of serum cytokines [ Time Frame: Up to 7 days after dosing ] [ Designated as safety issue: No ]
- Levels of blood biomarkers (interferon-alpha inducible genes) [ Time Frame: Up to 7 days after dosing ] [ Designated as safety issue: No ]
| Enrollment: | 26 |
| Study Start Date: | January 2008 |
| Study Completion Date: | March 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Escalating Dose of SD-101 |
Drug: SD-101
Single subcutaneous escalating dose
|
| Placebo Comparator: Placebo |
Drug: placebo
placebo
|
Detailed Description:
This is a Phase 1, randomized, single-blind, placebo-controlled study of five escalating dose levels of SD-101 in healthy male volunteers. The objectives of the study are to assess the safety, tolerability, pharmacokinetic profile, and pharmacodynamics of SD-101. Approximately 40 subjects will participate.
Once subjects have been consented, screened, and assigned to one of the dose levels of SD-101, subjects will receive a single subcutaneous injection of either SD-101 or placebo (PBS) in a ratio of 6:2.
Safety and tolerability will be evaluated by occurrence of adverse events, blood and urine laboratory tests, physical examination findings, vital signs , and electrocardiogram findings. Pharmacodynamics will be evaluated by levels of blood biomarkers and serum cytokines, and flow cytometric cell counts. Pharmacokinetics will be evaluated by levels of study drug in serum.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Signed, written, informed consent must be obtained from the subjects before any study-specific procedures are performed.
- Subject must be male and 18 years of age or older.
- Subject must be willing to submit to a urine drug screen and agree to abstain from alcohol, caffeine, and tobacco during the required stay in the Phase I Unit.
- Subject must be willing to abide by the rules of the Phase 1 Unit.
- Subjects whose sexual partners are of childbearing potential must agree to use an effective method of birth control (i.e., chemical contraceptives, barrier plus spermicide, intrauterine device) during the treatment phase and for 14 days post treatment.
- Must be negative for Hepatitis B and C and human immunodeficiency virus (HIV).
Exclusion Criteria:
- Females.
- Clinically significant active, acute, or chronic illness.
- History of coagulation or bleeding disorders.
- Clinically significant chronic or recent (within 21 days of dosing) acute gastrointestinal disorder with nausea, vomiting or diarrhea as a major symptom.
- Received any vaccine within 3 weeks of study entry or plans to be vaccinated within 6 weeks after study injection.
- History of significant cardiovascular or cerebrovascular disease.
- History of evaluation for autoimmune disease including SLE, rheumatoid arthritis (RA), scleroderma or thyroiditis.
- Significant psychiatric illness that could potentially interfere with the assessments during this study.
- Subjects who have had prior surgery or a major infection within 6 months of dosing.
- History of medications within 7 days of dosing, except vitamins and/or minerals.
- History of Gilbert's disease.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00599001
Locations
| United States, Texas | |
| Healthcare Discoveries, Inc. | |
| San Antonio, Texas, United States, 78209 | |
Sponsors and Collaborators
Dynavax Technologies Corporation
Investigators
| Principal Investigator: | Dennis Ruff, MD | Healthcare Discoveries, Inc. |
More Information
Additional Information:
No publications provided
| Responsible Party: | Eduardo Martins, MD, DPhil / Vice President, Clinical Development, Dynavax Technologies Corporation |
| ClinicalTrials.gov Identifier: | NCT00599001 History of Changes |
| Other Study ID Numbers: | DV3-HNV-01 |
| Study First Received: | January 11, 2008 |
| Last Updated: | April 21, 2008 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Dynavax Technologies Corporation:
|
healthy volunteer research subjects ISS phase 1 |
ClinicalTrials.gov processed this record on May 22, 2013